%0 Journal Article
%@ 0030-2414 (Druck-Ausg.), 1423-0232 (Online-Ausg.)
%A Ganten, Maria-Katharina
%A Schuessler, Max
%A Bruckner, Thomas
%A Ganten, Tom M.
%A Koschny, Ronald
%C Basel ; Freiburg
%D 2015
%F heidok:27248
%I Karger
%J Oncology
%K hepatocellular carcinoma , Sorafenib · pancreatic atrophy
%N 2
%P 88-94
%R 10.11588/heidok.00027248
%T Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
%U https://archiv.ub.uni-heidelberg.de/volltextserver/27248/
%V 89
%X Objective: To date, sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). Pancreatic atrophy has recently been reported in 2 patients as a novel side effect after long-term sorafenib treatment.     Methods: We retrospectively analyzed clinical and radiological data of patients with advanced HCC with long-term treatment of sorafenib (median 279 days, range 153–826 days). Pancreata were semi-manually segmented section by section to calculate the pancreas volumes before and under sorafenib treatment.     Results: Sorafenib reduced pancreatic volume in 18/19 (95%) HCC patients with a mean pancreatic volume loss of 25% (p = 0.002). Pancreatic volume loss depended on the dose (r = 0.36) and exposure time of sorafenib (r = 0.35) and was detectable as early as after 3 months of sorafenib treatment and already after a cumulative sorafenib dose of <100 g. Median overall survival was 13.2 months (range 7.8–31.3 months) but did not correlate with sorafenibinduced pancreatic volume reduction (hazard ratio 1.002, 95% confidence interval 0.981–1.060, p = 0.24).     Conclusion: We could confirm pancreatic atrophy as a novel adverse event of sorafenib therapy in HCC patients, correlating with sorafenib dose and exposure time.
%Z Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz bzw. Nationallizenz frei zugänglich.    This publication is freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.